BACKGROUND: Hydroxyurea improves laboratory parameters and prevents acute clinical complications of sickle cell anemia (SCA) in children and adults, but its effects on organ function remain incompletely defined. METHODS: To assess the safety and efficacy of hydroxyurea in young children with SCA and to prospectively assess kidney and brain function, 14 young children (mean age 35 months) received hydroxyurea at a mean maximum tolerated dose (MTD) of 28 mg/kg/day. RESULTS: After a mean of 25 months, expected laboratory effects included significant increases in hemoglobin, MCV and %HbF along with significant decreases in reticulocytes, absolute neutrophil count, and bilirubin. There was no significant increase in glomerular filtration rate by DTPA clearance or Schwartz estimate. Mean transcranial Doppler (TCD) velocity changes were -25.6 cm/sec (P < 0.01) and -26.8 cm/sec (P < 0.05) in the right and left MCA vessels, respectively. At study exit, no child had conditional or abnormal TCD values, and none developed brain ischemic lesions or vasculopathy progression by MRI/MRA. Growth and neurocognitive scores were preserved and Impact-on-Family scores improved. CONCLUSIONS: These pilot data indicate hydroxyurea at MTD is well-tolerated by both children and families, and may prevent chronic organ damage in young children with SCA. (c) 2008 Wiley-Liss, Inc.
BACKGROUND:Hydroxyurea improves laboratory parameters and prevents acute clinical complications of sickle cell anemia (SCA) in children and adults, but its effects on organ function remain incompletely defined. METHODS: To assess the safety and efficacy of hydroxyurea in young children with SCA and to prospectively assess kidney and brain function, 14 young children (mean age 35 months) received hydroxyurea at a mean maximum tolerated dose (MTD) of 28 mg/kg/day. RESULTS: After a mean of 25 months, expected laboratory effects included significant increases in hemoglobin, MCV and %HbF along with significant decreases in reticulocytes, absolute neutrophil count, and bilirubin. There was no significant increase in glomerular filtration rate by DTPA clearance or Schwartz estimate. Mean transcranial Doppler (TCD) velocity changes were -25.6 cm/sec (P < 0.01) and -26.8 cm/sec (P < 0.05) in the right and left MCA vessels, respectively. At study exit, no child had conditional or abnormal TCD values, and none developed brain ischemic lesions or vasculopathy progression by MRI/MRA. Growth and neurocognitive scores were preserved and Impact-on-Family scores improved. CONCLUSIONS: These pilot data indicate hydroxyurea at MTD is well-tolerated by both children and families, and may prevent chronic organ damage in young children with SCA. (c) 2008 Wiley-Liss, Inc.
Authors: Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang Journal: Blood Date: 2005-10-01 Impact factor: 22.113
Authors: T R Kinney; R W Helms; E E O'Branski; K Ohene-Frempong; W Wang; C Daeschner; E Vichinsky; R Redding-Lallinger; B Gee; O S Platt; R E Ware Journal: Blood Date: 1999-09-01 Impact factor: 22.113
Authors: A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban Journal: Blood Date: 1996-09-15 Impact factor: 22.113
Authors: Matthew M Heeney; Matthew R Whorton; Thad A Howard; Christina A Johnson; Russell E Ware Journal: J Pediatr Hematol Oncol Date: 2004-03 Impact factor: 1.289
Authors: F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky Journal: Blood Date: 1995-07-15 Impact factor: 22.113
Authors: Tonya Kratovil; Dorothy Bulas; M Catherine Driscoll; Barbara Speller-Brown; Robert McCarter; Caterina P Minniti Journal: Pediatr Blood Cancer Date: 2006-12 Impact factor: 3.167
Authors: Léon Tshilolo; George Tomlinson; Thomas N Williams; Brígida Santos; Peter Olupot-Olupot; Adam Lane; Banu Aygun; Susan E Stuber; Teresa S Latham; Patrick T McGann; Russell E Ware Journal: N Engl J Med Date: 2018-12-01 Impact factor: 91.245
Authors: Patrick T McGann; Omar Niss; Min Dong; Anu Marahatta; Thad A Howard; Tomoyuki Mizuno; Adam Lane; Theodosia A Kalfa; Punam Malik; Charles T Quinn; Russell E Ware; Alexander A Vinks Journal: Am J Hematol Date: 2019-06-12 Impact factor: 10.047
Authors: Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson Journal: Lancet Date: 2011-05-14 Impact factor: 79.321
Authors: Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware Journal: Am J Hematol Date: 2012-12-17 Impact factor: 10.047